Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462990 · ClinicalTrials.gov registry record · Phase 2
A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT05462990 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 101 participants.
The verdict
NCT05462990, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of the study was to find out if the investigational treatment named QUC398 had beneficial effects on osteoarthritis (OA) knee pain and knee cartilage, and if it was safe and tolerated.
Interventions
- DRUG Placebo
- DRUG QUC398
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2025-04-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05462990
The ClinicalTrials.gov registry entry for NCT05462990 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05462990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05462990 about?
NCT05462990 is a clinical study titled "A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA". The purpose of the study was to find out if the investigational treatment named QUC398 had beneficial effects on osteoarthritis (OA) knee pain and knee cartilage, and if it was safe and tolerated.
What is the current status of trial NCT05462990?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2022-11-09. Estimated completion is 2025-04-08.
What interventions are being tested in trial NCT05462990?
The interventions under investigation include: Placebo (DRUG), QUC398 (DRUG).
Who is sponsoring clinical trial NCT05462990?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.